Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinomaviaTRAIL-induced apoptotic pathway regulation
Open Access
- 22 December 2013
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 135 (2) , 308-318
Abstract
Ovarian cancer is the most lethal gynecologic malignancy, and clear cell adenocarcinoma of the ovary (OCCA), in particular, has a relatively poor prognosis among the ovarian cancer subtypes because of its high chemoresistance. Chromobox (CBX) 7 is a polycomb repressive complex 1 component that prolongs the lifespan of normal human cells by downregulating the INK4a/ARF expression which promotes cell‐cycle progression. However, recent reports studying the relationship between CBX7 expression and patient survival have differed regarding the tumor cell origins, and the precise role of CBX7 in human carcinomas remains obscure. In this study, we analyzed CBX7 expression by immunohistochemistry in 81 OCCA patients and evaluated its association with their clinical outcomes. Both the overall and progression‐free survival rates of the CBX7‐positive patients were significantly shorter than those of the CBX7‐negative patients (p < 0.05). CBX7 knockdown experiments using two OCCA cell lines, TOV21G and KOC‐7C, revealed that cell viability was significantly reduced compared to the control cells (p < 0.001). Expression microarray analysis revealed that apoptosis‐related genes, particularly tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL), were significantly upregulated in CBX7 knockdown cells (p < 0.01). We further confirmed that CBX7 knockdown resulted in TRAIL‐induced apoptosis in the OCCA cells. Thus, in this study, we showed for the first time that CBX7 was associated with a decreased OCCA prognosis. We also successfully demonstrated that the TRAIL pathway is a novel target for CBX7 expression modulation in these cells, and therapeutic agents utilizing the TRAIL pathway may be particularly effective for targeted OCCA therapy.Keywords
This publication has 33 references indexed in Scilit:
- Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates with Worsened PrognosisPLOS ONE, 2013
- Clear cell carcinoma of the ovary: A review of the literatureGynecologic Oncology, 2012
- Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studiesThe Lancet Oncology, 2012
- Roles of the Polycomb group proteins in stem cells and cancerCell Death & Disease, 2011
- Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian CancerInternational Journal of Gynecological Cancer, 2010
- Contents of Endometriotic Cysts, Especially the High Concentration of Free Iron, Are a Possible Cause of Carcinogenesis in the Cysts through the Iron-Induced Persistent Oxidative StressClinical Cancer Research, 2008
- RETRACTED ARTICLE: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locusOncogene, 2005
- Polycomb CBX7 has a unifying role in cellular lifespanNature Cell Biology, 2003
- Clinical characteristics of clear cell carcinoma of the ovaryCancer, 2000
- Ovarian clear cell adenocarcinomaGynecologic Oncology, 1989